药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Isoprenaline
Pralsetinib
Cholesterol may increase the excretion rate of Pralsetinib which could result in a lower serum level and potentially a reduction in efficacy.
Isoprenaline
Fostemsavir
Cholesterol may increase the excretion rate of Fostemsavir which could result in a lower serum level and potentially a reduction in efficacy.
Isoprenaline
Ripretinib
Cholesterol may increase the excretion rate of Ripretinib which could result in a lower serum level and potentially a reduction in efficacy.
Isoprenaline
Pralatrexate
Cholesterol may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy.
Isoprenaline
Selumetinib
Cholesterol may increase the excretion rate of Selumetinib which could result in a lower serum level and potentially a reduction in efficacy.
Isoprenaline
Tucatinib
Cholesterol may increase the excretion rate of Tucatinib which could result in a lower serum level and potentially a reduction in efficacy.
Isoprenaline
Ozanimod
Cholesterol may increase the excretion rate of Ozanimod which could result in a lower serum level and potentially a reduction in efficacy.
Isoprenaline
Rimegepant
Cholesterol may increase the excretion rate of Rimegepant which could result in a lower serum level and potentially a reduction in efficacy.
Isoprenaline
Ubrogepant
Cholesterol may increase the excretion rate of Ubrogepant which could result in a lower serum level and potentially a reduction in efficacy.
Isoprenaline
Glecaprevir
Cholesterol may increase the excretion rate of Glecaprevir which could result in a lower serum level and potentially a reduction in efficacy.
Isoprenaline
Pibrentasvir
Cholesterol may increase the excretion rate of Pibrentasvir which could result in a lower serum level and potentially a reduction in efficacy.
Isoprenaline
Lusutrombopag
Cholesterol may increase the excretion rate of Lusutrombopag which could result in a lower serum level and potentially a reduction in efficacy.
Isoprenaline
Darolutamide
Cholesterol may increase the excretion rate of Darolutamide which could result in a lower serum level and potentially a reduction in efficacy.
Isoprenaline
Tazemetostat
Cholesterol may increase the excretion rate of Tazemetostat which could result in a lower serum level and potentially a reduction in efficacy.
Isoprenaline
Copanlisib
Cholesterol may increase the excretion rate of Copanlisib which could result in a lower serum level and potentially a reduction in efficacy.
Isoprenaline
Rucaparib
Cholesterol may increase the excretion rate of Rucaparib which could result in a lower serum level and potentially a reduction in efficacy.
Isoprenaline
Voxilaprevir
Cholesterol may increase the excretion rate of Voxilaprevir which could result in a lower serum level and potentially a reduction in efficacy.
Isoprenaline
Alpelisib
Cholesterol may increase the excretion rate of Alpelisib which could result in a lower serum level and potentially a reduction in efficacy.
Isoprenaline
Abemaciclib
Cholesterol may increase the excretion rate of Abemaciclib which could result in a lower serum level and potentially a reduction in efficacy.
Isoprenaline
Glasdegib
Cholesterol may increase the excretion rate of Glasdegib which could result in a lower serum level and potentially a reduction in efficacy.